Platform Trials Are Rewriting the Rules of Evidence Generation. Regulators Haven’t Caught Up.
Adaptive platform trials like RECOVERY and REMAP-CAP are transforming infectious disease research, but FDA and EMA guidance still lags...
Platform Trials
When the Protocol Keeps Changing: What MAMS Trials Actually Cost Sites to Run
The OCTOPUS progressive MS platform trial has enrolled 700+ participants across dynamic arms. Here's what sites need to know...
The Neurological Drug Development Machine Is Broken. Platform Trials Are the Wrench.
MAMS platform trials could cut neurodegenerative drug timelines—but adaptive stopping rules and FDA guidance gaps threaten to stall the...
The Trial Architecture Neurodegenerative Disease Has Always Needed — And Kept Refusing to Build
MAMS platform trials could end neurology's 99.6% drug failure rate. The Lancet just made the case. Here's what the...
The Platform Trial Takeover: Neurology’s Last Best Chance to Stop Failing Patients
Multi-arm multi-stage platform trials could cut neurodegenerative drug timelines in half—but FDA adaptive design rules haven't caught up with...
Platform Trials Are Neurology’s Best Bet — So Why Is the FDA Still Treating Them Like Experiments?
The Lancet calls MAMS platform trials the fix for neurodegenerative drug failure. With 182 Alzheimer's trials active in 2025,...
The Neurodegenerative Trial Problem Has a Design Solution—But Sponsors Keep Ignoring It
MAMS platform trials could slash neurodegenerative drug development timelines—so why are sponsors still running serial Phase 2s for Alzheimer's...
Neurodegenerative Drug Development Has a 2% Success Rate. Platform Trials Are the Only Honest Response.
With 51% of Alzheimer's disease-modifying compounds failing Phase III, The Lancet's case for MAMS platform trials in neurology isn't...